A phase III randomized trial comparing the efficacy and safety of the 3-monthly 10.8-mg depot of Zoladex with the monthly 3.6-mg depot in patients with advanced prostate cancer. Dutch South East Cooperative Urological Group.
作者信息
Dijkman G A, Debruyne F M, Fernandez del Moral P, Plasman J W, Hoefakker J W, Idema J G, Sykes M
机构信息
Department of Urology, St. Ignatius Hospital, Breda, The Netherlands.
出版信息
Eur Urol. 1994;26 Suppl 1:1-2. doi: 10.1159/000475421.
PMID:7737253
Abstract
摘要
相似文献
1
A phase III randomized trial comparing the efficacy and safety of the 3-monthly 10.8-mg depot of Zoladex with the monthly 3.6-mg depot in patients with advanced prostate cancer. Dutch South East Cooperative Urological Group.一项III期随机试验，比较每三个月注射10.8毫克诺雷德长效注射剂与每月注射3.6毫克诺雷德长效注射剂治疗晚期前列腺癌患者的疗效和安全性。荷兰东南部泌尿外科学合作组。
Eur Urol. 1994;26 Suppl 1:1-2. doi: 10.1159/000475421.
2
A randomised trial comparing the safety and efficacy of the Zoladex 10.8-mg depot, administered every 12 weeks, to that of the Zoladex 3.6-mg depot, administered every 4 weeks, in patients with advanced prostate cancer. The Dutch South East Cooperative Urological Group.一项随机试验，比较每12周注射一次的10.8毫克戈舍瑞林长效注射剂与每4周注射一次的3.6毫克戈舍瑞林长效注射剂在晚期前列腺癌患者中的安全性和有效性。荷兰东南部泌尿外科合作组。
Eur Urol. 1995;27(1):43-6. doi: 10.1159/000475122.
3
4
A new longer-acting LHRH analog depot: preliminary results of a Dutch open phase II clinical study on a 10.8 mg Zoladex 3-monthly depot.一种新型长效促黄体生成激素释放激素（LHRH）类似物长效注射剂：一项关于每三个月注射一次10.8毫克戈舍瑞林长效注射剂的荷兰开放性II期临床研究的初步结果
Eur Urol. 1990;18 Suppl 3:22-5. doi: 10.1159/000463974.
5
Three-month depot of goserelin acetate: clinical efficacy and endocrine profile. Dutch South East Cooperative Urological Group.
Urology. 1996 Dec;48(6):894-900. doi: 10.1016/s0090-4295(96)00300-7.
6
[A new LH-RH agonist for treatment of prostate cancer, 3-month controlled-release formulation of goserelin acetate (Zoladex LA 10.8 mg depot)--outline of pre-clinical and clinical studies].[一种用于治疗前列腺癌的新型促黄体生成素释放激素激动剂，醋酸戈舍瑞林3个月控释制剂（诺雷德长效注射剂10.8毫克）——临床前及临床研究概述]
Gan To Kagaku Ryoho. 2002 Sep;29(9):1675-87.
7
3-month formulation of goserelin acetate ('Zoladex' 10.8-mg depot) in advanced prostate cancer: results from an Italian, open, multicenter trial.醋酸戈舍瑞林（“诺雷德”10.8毫克长效注射剂）3个月剂型用于晚期前列腺癌：一项意大利开放性多中心试验的结果
Urol Int. 2003;70(4):316-20. doi: 10.1159/000070142.
8
9
[Randomized study comparing zoladex versus zoladex plus flutamide in treatment of advanced cancer of the prostate].比较戈舍瑞林与戈舍瑞林加氟他胺治疗晚期前列腺癌的随机研究
Helv Chir Acta. 1992 Oct;59(3):477-83.
10
Randomised crossover trial to assess the tolerability of LHRH analogue administration.评估促黄体生成素释放激素类似物给药耐受性的随机交叉试验。
Prostate Cancer Prostatic Dis. 2003;6(2):187-9. doi: 10.1038/sj.pcan.4500625.
引用本文的文献
1
Phase 3, open-label, randomized study comparing 3-monthly with monthly goserelin in pre-menopausal women with estrogen receptor-positive advanced breast cancer.一项3期开放标签随机研究，比较每3个月一次与每月一次戈舍瑞林用于雌激素受体阳性绝经前晚期乳腺癌女性的疗效。
Breast Cancer. 2016 Sep;23(5):771-9. doi: 10.1007/s12282-015-0637-4. Epub 2015 Sep 9.
Zotero 插件